Skip to content

The Influence of Polymeric Versus Oligomeric Enteral Feeding on Tolerance and Nutritional Status in Paediatric Intensive Care Pilot

The Influence of Polymeric Versus Oligomeric Enteral Feeding on Tolerance and Nutritional Status in Paediatric Intensive Care: Prospective Randomized Pilot Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05271565
Acronym
Polygomerpilot
Enrollment
40
Registered
2022-03-09
Start date
2022-04-21
Completion date
2023-08-31
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enteral Feeding Intolerance

Keywords

Enteral feeding, Enteral nutrition, Paediatric patient, Oligomeric, Polymeric

Brief summary

Malnutrition is associated with negative impact on morbidity and mortality of critically ill patients. Therefore, in patients unable of peroral intake, the nutritional support is indicated. The preferred form of nutritional support is enteral, the more natural form, compared to parenteral. The enteral nutrition is cheaper and is associated with better outcomes and lower incidence of associated complications. The intolerance of enteral feeding is common in critically ill patients, and is associated with insufficient energy and protein intake, that could be linked with the complications such aspiration pneumonia. The optimization of enteral feeding tolerance is therefore one of the research priorities. Implementation of feeding protocols is associated with better tolerance. The enteral feeding could be administered as a oligomeric or polymeric formula. The are preliminary data from adult population pointing at better tolerance of oligomeric feeding formula.

Detailed description

After Ethics Committee approval, all paediatric patients admitted to the paediatric intensive care unit (PICU) will underwent PICU screening. In case of eligible for inclusion in to the study, the baseline parameters a demographics will be evaluated together with the initial laboratory sampling after approval and singed the informed consent by the legal guardian of the patient. Patients will be randomized by the online randomizer to the oligomeric and polymeric enteral nutrition group. Polymeric (control group): Patients indicated for at least 2 days of enteral nutrition by the gastric tube. The nutritional support will be initiated after initial haemodynamic stabilization (blood levels of lactate normalization, norepinephrine infusion \<0,1 ug/kg/min) in the 48-hours interval from admission in form of bolus administration of polymeric formula. The initial dose will be 10% of the target volume (by Schofield equation). The gastric residual volume will be evaluated after 4 hours from bolus dose. In case of gastric residual volume lower than half of previously administered dose, the next dose will be elevated by 10% with the aim to reach the target dose in 48 hours. In case of higher residual volume, the same amount will be administered with the metoclopramid (3 times per day). In case of persistent residual volume higher than half of initial dose in 12 hours, the erythromycin will be initiated for 3 days. The bolus enteral feeding will be administered at the predefined time 5/day (6:00, 10:00, 14:00, 18:00, 22:00). The last gastric decompression is planned ad 24:00. The aim is to reach energetic goal defined by Schofield equation. Interventional (oligomeric group): Patients indicated for at least 2 days of enteral nutrition by the gastric tube. The nutritional support will be initiated after initial haemodynamic stabilization (blood levels of lactate normalization, norepinephrine infusion \<0,1 ug/kg/min) in the 48-hours interval from admission in form of bolus administration of oligomeric formula. The initial dose will be 10% of the target volume (by Schofield equation). The gastric residual volume will be evaluated after 4 hours from bolus dose. In case of gastric residual volume lower than half of previously administered dose, the next dose will be elevated by 10% with the aim to reach the target dose in 48 hours. In case of higher residual volume, the same amount will be administered with the metoclopramid (3 times per day). In case of persistent residual volume higher than half of initial dose in 12 hours, the erythromycin will be initiated for 3 days. The bolus enteral feeding will be administered at the predefined time 5/day (6:00, 10:00, 14:00, 18:00, 22:00). The las gastric decompression is planned ad 24:00. The aim is to reach energetic goal defined by Schofield equation.

Interventions

DIETARY_SUPPLEMENTOligomeric enteral feeding

Oligomeric enteral formula

DIETARY_SUPPLEMENTPolymeric enteral feeding

Polymeric enteral feeding will be administered to the PICU patients

Sponsors

Masaryk University
CollaboratorOTHER
Brno University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

The patients and the legal guardians will be blinded

Intervention model description

Monocentric randomized pilot controlled trial with 2 groups: interventional (oligomeric formula) and control (polymeric)

Eligibility

Sex/Gender
ALL
Age
1 Months to 19 Years
Healthy volunteers
No

Inclusion criteria

* PICU patients indicated for nutritional support by enteral feeding (gastric or jejunal)

Exclusion criteria

* Enteral feeding contraindicated * Persistent haemodynamic instability * Informed consent not signed * Acute pancreatitis * Recent upper gastrointestinal surgery * Gut perforation * Ileus

Design outcomes

Primary

MeasureTime frameDescription
The amount of energy delivery at 3rd dayon the 3rd day after study inclusionThe amount of delivered energy at 3rd day according to the defined energy goal by derived from Schofield equation (defined after 15 enteral bolus doses)
The amount of protein delivery at 3rd dayon the 3rd day after study inclusionThe amount of delivered protein at 3rd day according to the defined protein goal by derived from Schofield equation (defined after 15 enteral bolus doses)

Secondary

MeasureTime frameDescription
The amount of protein delivery at 5th dayon the 5th day after study inclusionThe amount of protein delivered at 5th day according to the defined protein delivery goal by derived from Schofield equation
The amount of energy delivery at 7th dayon the 7th day after study inclusionThe amount of delivered energy at 7th day according to the defined energy goal by derived from Schofield equation
The amount of protein delivery at 7th dayon the 7th day after study initiationThe amount of protein delivered at 7th day according to the defined protein delivery goal by derived from Schofield equation
The daily energy deliveryin 7 days after study initiationThe daily amount of energy delivery
The daily protein deliveryin 7 days after study initiationThe daily amount of protein delivery
The time needed to achieve the protein targetin 7 days after study initiationThe time needed to achieve the protein target according to the Schofield equation
The time needed to achieve the energy targetin 7 days after study initiationThe time needed to achieve the energy target according to the Schofield equation
The mean gastric residual volumein 7 days after study initiationThe mean gastric residual volume
The time to first stoolin 7 days after study initiationThe time to first stool from study initiation
The daily number of stoolin 7 days after study initiationThe daily number of stool from study initiation
Nutritional parameters 1 - albuminin 7 days after study initiationalbumin plasmatic levels
Nutritional parameters 1 - prealbuminin 7 days after study initiationprealbumin plasmatic levels
The daily gastric residual volumein 7 days after study initiationThe daily gastric residual volume
The amount of energy delivery at 5th dayon the 5th day after study inclusionThe amount of delivered energy at 5th day according to the defined energy goal by derived from Schofield equation

Countries

Czechia

Contacts

Primary ContactJozef Klučka, assoc.prof.MD., Ph.D.
klucka.jozef@fnbrno.cz+420532234696
Backup ContactMilan Kratochvíl, MD. EDIC
kratochvil.milan@fnbrno.cz+420532234696

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026